Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin

NCT00495391 is registered in ClinicalTrials.gov with Romark Laboratories L.C. as lead sponsor.

NCT NCT00495391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00495391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin
Lead sponsor
Romark Laboratories L.C.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
February 28, 2010
Enrollment
64 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c